Mahin F. Arastu

The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

K. Rhodes, S. Salloway, J. Sevigny, 2016, Nature.

Sustained Release Chemotherapeutic Microspheres Provide Superior Efficacy over Systemic Therapy and Local Bolus Infusions

R. Bartus, D. Emerich, R. Dean, 2002, Pharmaceutical Research.

Addendum: The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease

K. Rhodes, S. Salloway, J. Sevigny, 2017, Nature.

Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone

M. Todtenkopf, D. Gastfriend, D. Deaver, 2008, Pharmacology Biochemistry and Behavior.

BIIB042, a novel γ-secretase modulator, reduces amyloidogenic Aβ isoforms in primates and rodents and plaque pathology in a mouse model of Alzheimer's disease

K. Rhodes, Lin Xu, Tina Talreja, 2016, Neuropharmacology.